National Institutes of Health, a Component of the US Dept. of Health & Human Services

Florida State University Research Foundation, Inc.

University of Pennsylvania

New York University

The Johns Hopkins University

The Rockefeller University

Icahn School of Medicine at Mount Sinai

Forschungsverbund Berlin E.v.

The Brigham and Women's Hospital, Inc.

Loyola University of Chicago

Other

Wenwei Huang

Wei Ping Zheng

Ruili Huang

Khalida Shamim

Hengli Tang

Hongjun Song

Miao Xu

Emily M Lee

Craig J Thomas

Guoli Ming

Marvin C Gershengorn

Susanne Neumann

Noel Terrence Southall

Dan R Littman

James Inglese

Jun R Huh

Steven Titus

Gregory J Tawa

Gerd Krause

Philip Edward Sanderson

Xiuli Huang

Bruce M Raaka

Hao Li

Gunnar Kleinau

Barry S Coller

Min Shen

Jian-kang Jiang

Marta Filizola

Erika Elaine Englund

Joshua McCoy

Guo-Li Ming

Arthur Lee

Asaf Alimardanov

Paul B Yu

Kim C Williamson

Paresma R Patel

Junfeng Huang

Anil Mathew Tharappel

Wei Sun

Hangmao Sun

Xiao Lu

Myunghoon Kim

Shu Yang

Meghan J Orr

Menghang Xia

Zhexing Wen

Yichen Cheng

Yi Zhou

Jian-Kang Jiang

Joshua Mccoy

Wei Zheng

The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.

Method for inhibiting dengue virus infection

Method for inhibiting Zika virus infection

Disclosed are compounds of formula (I) and formula (II): wherein R, R, A, and B are as defined herein. Also disclosed is a method of blocking transmission of aparasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

Compounds and method for blocking transmission of malarial parasite

The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sj&#xf6;gren's syndrome, or diffuse intrinsic pontine glioma (DIPG).

ALK2 inhibitors and methods for inhibiting BMP signaling

Anti-flavivirus compounds and methods of use

The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as dengue virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as dengue virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such dengue virus infections.

Emetine compounds for treatment and prevention of flavivirus infection

Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R, R, A, and B are as defined herein. Also disclosed is a method of blocking transmission of aparasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat. 

The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

Compounds and methods for treatment and prevention of Flavivirus infection

Amido compounds are disclosed that have a formula represented by the following: and wherein n1, n2, R, R, R, R, R, R, and Rare as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.

Amido compounds as ROR&#x3b3;t modulators and uses thereof

The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

Amido compounds are disclosed that have a formula represented by the following: and wherein Cy, Cy, n1, n2, R, R, R, R, R, R, and Rare as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.

Growing community of inventors

Rockville, MD, United States of America

Wenwei Huang